Skip to main content
SpringerLink
Log in

Cardiac amyloidosis

Patisiran is beneficial for the treatment of TTR cardiac amyloidosis

  • Research Highlight
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • Maurer, M. S. et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 389, 1553–1565 (2023)

    Article  CAS  PubMed  Google Scholar 

Related article

  • Aimo, A. et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 19, 655–667 (2022)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Cardiology http://www.nature.com/nrcardio/

    Irene Fernández-Ruiz

Authors
  1. Irene Fernández-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Irene Fernández-Ruiz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernández-Ruiz, I. Patisiran is beneficial for the treatment of TTR cardiac amyloidosis. Nat Rev Cardiol 21, 8 (2024). https://doi.org/10.1038/s41569-023-00955-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-023-00955-2

  • Springer Nature Limited

Search

Navigation